CYP-002 is under clinical development by Cynata Therapeutics and currently in Phase III for Osteoarthritis. According to GlobalData, Phase III drugs for Osteoarthritis have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CYP-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CYP-002 overview
CYP-002 is under development for the treatment of critical limb ischemia, cytokine release syndrome, asthma, osteoarthritis, myocardial infarction, ventricular arrhythmia and coronary heart disease. The stem cell therapy is a regenerative medicine therapy consisting of mesenchymoangioblast which is a common precursor for both mesenchymal stem cells (MSCs) and endothelial cells. This stem cell therapy incorporates Cymerus platform stem cell technology. It is administered through intramuscular route.
Cynata Therapeutics overview
Cynata Therapeutics is a stem cell and regenerative medicine company. It develops and commercializes Cymerus, a stem cell platform technology used for the production of mesenchymal stem cells (MSCs) for human therapeutic use. Its proprietary technology platform utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor for generating mesenchymoangioblasts (MCAs) in manufacturing the Cymerus MSC therapeutic products for the treatment of osteoarthritis, brain cancer and melanoma, Crohn’s disease, asthma, acute respiratory distress syndrome and heart attack. Its lead MSC product candidate CYP-001 is used for the prevention and treatment of Graft-versus-host-disease (GvHD). The company has operations in Ireland and, the US. Cynata Therapeutics is headquartered in Carlton, Australia.
For a complete picture of CYP-002’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
